Targovax ASA: Abstracts accepted for poster presentation at the ESMO 2017 Congress
Oslo, Norway, 23 August 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that three abstracts been have accepted for poster presentation during the European Society for Medical Oncology (ESMO) 2017 Congress to be held in Madrid, Spain from 8-12 September. The details of the abstracts can be found below. Poster session: Poster Display sessionAbstract title: TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma